The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index which is down by 0.35%.

Brain-focused company, Argenica Therapeutics (ASX:AGN), has just been awarded a US patent relating to the use of its lead drug, ARG-007.

The patent covers the use of ARG-007 as a therapeutic compound to prevent brain cell death in patients with stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy (HIE).

“These are conditions with huge unmet medical needs in the US, and represent large addressable markets that the company will look to target,” says Argenica CEO, Dr Liz Dallimore.

ARG-007 is a neuroprotective drug which has shown efficacy in animal models to reduce brain cell death.

Today’s patent claims also cover the use of ARG-007 in Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Parkinson’s disease, motor neuron disease, neuropathic pain, spinal cord injury, and epilepsy.

Meanwhile, Antisense Therapeutics (ASX:ANP) has submitted to the US FDA a toxicology protocol report for its lead drug, TL1102.

The protocol synopsis covers a nine-month chronic monkey toxicology study in the use of ATL1102 to treat Duchenne Muscular Dystrophy (DMD).

The aim of the report is to get an FDA approval to allow the dosing of patients with ATL1102 beyond six months.

ANP expects to receive feedback from the FDA in the first quarter of 2022.


Argenica and Antisense share prices today:


In other ASX health news this morning

EBOS Group (ASX:EBO) has made a takeover play for LifeHealthcare for approximately $1.167 billion.

LifeHealthcare is one of the largest independent distributors of third party medical devices and manufactured allograft material in Australia, New Zealand and South East Asia.

AdAlta (ASX:1AD) says that initial testing of AD-214, its lead drug to treat fibrotic diseases, points to a successful application with nebulisation devices.

The company reported that between 17-46% of an AD-214 dose delivered from commercial nebulisers could be deposited in the smallest human lung airways, exceeding AdAlta’s pre-study expectations of 10%.

This is an important early step to ensure that AD-214 can be successfully converted to fine droplets or aerosols, for penetration to the smaller airways of the lungs.

Cancer diagnostics company Pacific Edge (ASX:PEB) has reached its first commercial agreement of scale in Australia with Melbourne-based Northern Health, a company that has over 5,700 professional staff.

Under the deal, urologists at Northern Health will use PEB’s Cxbladder Monitor to help manage patients undergoing surveillance following treatment of their bladder cancer.

Cannabis stock Auscann (ASX:AC8) has held a positive pre-submission meeting with the FDA to discuss the development and regulatory pathway for CPAT-01 in the US.

CPAT-01 is a cannabinoid-based veterinary medicine used to manage pain and inflammation  in dogs with osteoarthritis, a market the company says is worth $1bn.

EMVision Medical Devices (ASX:EMV) says a presentation of its medical imaging technology has been accepted for the prestigious International Stroke Conference to be held in New Orleans in February 2022.

Stroke neurologist and Australian Stroke Alliance clinical expert Dr Angela Dos Santos will be giving the presentation.



Share prices today: